Literature DB >> 11797295

[Role of adjuvant therapy in uterine sarcoma: experience of the Curie Institute].

E Deniaud-Alexandre1, L Chauveinc, A de la Rochefordière, X Sastre, K B Clough.   

Abstract

PURPOSE: Uterine sarcoma is a rare disease and survival is poor. From 1975 to 1995, 73 uterine sarcomas were treated at the Curie Institute, and we analysed prognostics factors of survival. PATIENTS AND METHODS: Seventy-one patients underwent primary surgery, in most cases a radical non conservative surgery and a lymphadenectomy. Every patient had an irradiation (external beam irradiation and/or brachytherapy), and 24 patients received adjuvant chemotherapy. We observed that youngest patients had more leiomyosarcomas and low histologic grade tumours. Median survival was 42 months, and 5-years survival and local control were 36 and 68% respectively. Pelvic recurrences were most often before 2 years. This series demonstrates the impact of adjuvant irradiation on local control. This impact was stronger if the tumour had a high histologic grade (p < 0.01). However, irradiation, as well as chemotherapy, had no impact on the survival.
CONCLUSION: The study confirmed that irradiation enable a better local control. However modalities of radiation therapy (brachytherapy and/or external beam radiotherapy, dose, volume), are still controversed.

Entities:  

Mesh:

Year:  2001        PMID: 11797295     DOI: 10.1016/s1278-3218(01)00133-0

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Uterine sarcomas in Port Harcourt, Nigeria: a 12-year clinico-pathologic study.

Authors:  D Seleye-Fubara; S A Uzoigwe
Journal:  Afr Health Sci       Date:  2007-03       Impact factor: 0.927

2.  Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.

Authors:  M A Voss; N Gordon; S Maloney; R Ganesan; L Ludeman; K McCarthy; R Gornall; G Schaller; W Wei; F Berditchevski; S Sundar
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.